defenseworld.net · 20 jul

Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System

California Public Employees Retirement System raised its position in Biogen Inc. (NASDAQ: BIIB) by 3.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 340,903 shares of the biotechnology company's stock after buying an additional 10,097 shares during the

prnewswire.com · 16 jul

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program.

zacks.com · 15 jul

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

globenewswire.com · 15 jul

Biogen Appoints Michael J. Parini as Chief Legal Officer

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen's global legal and compliance functions.

seekingalpha.com · 14 jul

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

marketbeat.com · 14 jul

Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.

zacks.com · 14 jul

Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

schaeffersresearch.com · 14 jul

Stocks Steady as Upbeat Inflation Battles IBM Earnings

Stocks are cautiously higher midday, as cooler inflation helps investors forget about higher oil prices